Michael Pilo

Michael focuses his practice on complex corporate transactions, with particular emphasis on representing issuers and investment banks in the technology, crypto and life sciences industries in public and private capital markets deals, including initial public offerings, high-yield bond offerings, private placements, ATMs and specialty finance transactions involving SPACs and REITs. He regularly counsels public company clients and their advisors on issues including securities law compliance, corporate governance practices and disclosure obligations.

Prior to joining Baker McKenzie, Michael advised on the following matters:

Equity Offerings

• Informatica’s* USD 841 million initial public offering and USD 408 million follow-on offering
• BioAge’s USD 238 million initial public offering and concurrent private placement
• bluebird bio’s* USD 500 million follow-on offering
• Cerulean Pharma’s* USD 60 million initial public offering
• Change Healthcare’s USD 640.7 million initial public offering
• Clementia Pharmaceuticals’* USD 120 million initial public offering and USD 70.26 million follow-on offering
• Dimension Therapeutics’* USD 71.5 million initial public offering
• Habit Restaurants’ USD 90 million initial public offering and USD 154.8 million follow-on offering
• Idera Pharmaceuticals’* USD 50 million initial public offering
• Karyopharm Therapeutics’* USD 108.8 million initial public offering
• Kiniksa Pharmaceuticals’* USD 152.6 million initial public offering
• LogicBio Therapeutics’ USD 70 million initial public offering and USD 50 million follow-on offering

• Listed, The Legal 500, US Capital Markets: Equity Offerings, 2022-2023